The Cité des sciences is dedicating a day to the solar eclipse visible from Paris on 12 August 2026. On the program: workshops, mini-lectures, Sun watching, eclipse tracking, and the Night of the ...

Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. A dose of Wegovy, a drug used for weight loss, is ...

Markets opened Q3 lower as strong labor data cooled rate-cut hopes ahead of Fed Chair Warsh's remarks at the ECB forum in Portugal. NKE slid in premarket despite beating EPS by 59 cents, while SPY ...

Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge. The move could unlock a vast new ...

Some Medicare patients will be able to access to GLP-1 medication for weight loss for the first time starting July 1, paying a $50 monthly copay through a new program designed to make the drugs more ...

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Donate to help seniors afford essentials they need today and ...

In August, a celestial spectacle will draw millions to a sparsely populated swath of Spain. Visitors will find the region is full of earthly wonders, too. The medieval Castle of Ucero, near the city ...

Share on Pinterest An estimated 14 million Medicare Part D recipients could obtain Wegovy, Foundayo, and Zepbound for $50 per month. Johner Images/Getty Images Federal officials announced the launch ...

Starting in July, some Medicare beneficiaries will be able to access GLP-1 medications by paying one flat fee per month. The temporary program is set to run for a year-and-a-half through the end of ...

A partial solar eclipse is happening today (Sept. 21), offering skywatchers a chance to see the moon appear to take a "bite" out of the sun. The eclipse begins at 1:29 p.m. EDT (1729 GMT), reaching ...

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...